A convergent synthesis provided nearly perfect τ-ADP-ribosylated histidine isosteres (His*-τ-ADPr) via a copper(I)-catalyzed cycloaddition between an azido-ADP-ribosyl analogue and an oligopeptide carrying a propargyl glycine. Both α- and β-configured azido-ADP-ribosyl analogues have been synthesized. The former required participation of the C-2 ester functionality during glycosylation, while the latter was obtained in high stereoselectivity from an imidate donor with a nonparticipating para-methoxy benzyl ether. Four His*-τ-ADPr peptides were screened against a library of human ADP-ribosyl hydrolases.
A convergent synthesis provided nearly perfect τ-ADP-ribosylated histidine isosteres (His*-τ-ADPr) via a copper(I)-catalyzed cycloaddition between an azido-ADP-ribosyl analogue and an oligopeptide carrying a propargyl glycine. Both α- and β-configured azido-ADP-ribosyl analogues have been synthesized. The former required participation of the C-2 ester functionality during glycosylation, while the latter was obtained in high stereoselectivity from an imidate donor with a nonparticipating para-methoxy benzyl ether. Four His*-τ-ADPr peptides were screened against a library of human ADP-ribosyl hydrolases.
A wide array of posttranslational
modifications (PTMs), varying from small alterations (e.g., methylation)
to the introduction of complete proteins (e.g., ubiquitination), are
essential for regulatory control of protein activity. Although nicotinamide
adenine dinucleotide (NAD+) is commonly known for its role
as a redox cofactor, it also participates in a PTM called adenosine
diphosphate-ribosylation (ADP-ribosylation). In this PTM, the adenosine
diphosphate ribose (ADPr) moiety is covalently attached to specific
amino acid side chains of the targeted protein by substitution of
the nicotinamide residue. In humans, this process is primarily facilitated
by ADP-ribosyl transferases termed PARPs,[1] and the resulting modification can be either mono-ADP-ribosylation
(MARylation) when a single ADPr molecule is introduced or poly-ADP-ribosylation
(PARylation) when longer linear or branched ADPr polymers are formed.
The latter process can be mediated by only a small subset of PARPs:
PARP1, PARP2, PARP5a, and PARP5b. Ever since the first isolation of
poly-ADPr chains[2] and the identification
of the transferase enzyme,[3] this PTM has
received ever increasing attention because of the many roles it plays
in various biological events. However, progress has been slowed down
due to the lack of appropriate tools to study this modification. Advances
in mass spectrometry revealed the breadth of possible amino acid acceptors,
including glutamate, aspartate, arginine,[4] lysine,[5] cysteine,[6] histidine,[7,8] tyrosine,[9,10] and
serine.[11] A complex regulatory network
of proteins “writing”, “reading”, and
“erasing” the ADP-ribosylation[12,13] is responsible for the huge structural diversity of the “ADP-ribosylome”.
Due to such structural diversity, ADP-ribosylation allows for the
spatiotemporal and context specific regulation of a wide variety of
cellular processes including DNA damage response, replication, transcription,
and cellular signaling (e.g., WNT signaling).[14−17] Among the different acceptor
residues, serine has emerged as the primary target in DNA damage-induced
ADP-ribosylation.[18−20] Recent proteomic studies have also drawn attention
toward the occurrence of lower-frequency modifications at tyrosine
and histidine sites.[7,8,21] The
identification of these new flavors of stress-induced ADP-ribosylation
is suggestive of a specialized control mechanism for subprocesses
within the DNA-damage response (DDR). For an identification and characterization
of the responsible “writers”, “readers”,
and “erasers” as well as an examination of their cellular
function, well-defined molecular tools are indispensable.To
generate tools to study histidine ADP-ribosylation, we reasoned
that click chemistry could be exploited to create a nearly perfect
isostere of ADP-ribosylated histidine (Figure A). Although the exact structure of ADP-ribosylated
histidine (His-ADPr) has not yet been determined, we hypothesize here
that ADPr is introduced at the τ-position of the imidazole functionality,
most likely via an α-configured linkage. This hypothesis is
based on the isolation of ribosylated and ADP-ribosylated histidine
metabolites[22,23] combined with the known stereospecificity
of PARP enzymes. The suspected 1,4-substitution pattern can be mimicked
via a Cu(I)-catalyzed azide–alkyne cycloaddition (CuAAC), known
for its high regioselectivity, with an azido-ADPr analogue and an
oligopeptide carrying a propargyl click handle at a specific position.
The use of CuAAC has been successfully implemented before in the synthesis
of ADP-ribosylated oligopeptides and proteins.[24−26] Here, the convergent
syntheses of both α- and β-configured ADP-ribosylated
histidine mimetics 1–4 (Figure B) are described.
Figure 1
(A) Proposed structure
of ADP-ribosylated histidine (X = CH) under
physiological conditions. Based on histidine metabolites and the α-selective
introduction of PARPs, it is suggested that ADPr is attached to the
imidazole functionality at the τ-nitrogen through an α-configured
glycosidic bond. An ADP-ribosylated histidine isostere (X = N) can
be obtained through CuAAC, where the imidazole functionality is replaced
by a triazole moiety. (B) Structures of the ADP-ribosylated histidine
mimetics described in this paper.
(A) Proposed structure
of ADP-ribosylated histidine (X = CH) under
physiological conditions. Based on histidine metabolites and the α-selective
introduction of PARPs, it is suggested that ADPr is attached to the
imidazole functionality at the τ-nitrogen through an α-configured
glycosidic bond. An ADP-ribosylated histidine isostere (X = N) can
be obtained through CuAAC, where the imidazole functionality is replaced
by a triazole moiety. (B) Structures of the ADP-ribosylated histidine
mimetics described in this paper.The target oligopeptides 1–4 are
based on two potential His-ADPr sites, located on histone PARylation
factor 1 (HPF1) and PARP1, respectively, that have been identified
in recent proteomic studies.[27] We aimed
to assemble the peptides by a late-stage click reaction between the
fully deprotected propargyl-glycine containing peptides and the α-
and β-ADP-ribosyl azides 22 and 25, which in turn can be obtained from the two anomeric azido ribose
5-phosphates (9 and 17) and known adenosine
phosphoramidite 20 using our P(III)–P(V) coupling
method.[28]Synthesis of the β-configured
5-phosphorylribofuranoside 9 started with commercially
available ribofuranose tetraacetate
(Scheme ). Owing to
neighboring group participation of the C-2-O-acetyl,
the desired β-azide was acquired with excellent stereoselectivity.[29] After a series of standard protecting group
manipulations, the fully protected azidoribofuranoside 7 was obtained, of which the silyl ether was selectively removed under
acidic conditions. Phosphitylation with bis(fluorenylmethyl)-N,N-diisopropyl phosphoramidite under influence
of pyridine-1-ium chloride as an activator provided the corresponding
phosphite which was oxidized with t-BuOOH to yield
1-β-azido-5-phosphorylribofuranoside 9.
Scheme 1
Synthesis
of the β-Configured 1-Azido-5-phosphorylribofuranoside 9
The assembly of the α-configured
1-azido-5-phosphorylribofuranoside
requires a nonparticipating protection group at the C-2-hydroxyl to
stereoselectively introduce the α-azido group. To this end,
suitably protected imidate 14 was prepared from d-ribose in 5 steps (Scheme ).[30] Activation of the ribosyl
donor 14 with trimethylsilyl triflate at −60 °C
in the presence of trimethylsilyl azide provided ribosyl azide 15 with excellent stereoselectivity (α/β = 14:1, Scheme B). Removal of the
PMB protecting groups proved difficult at this point using either
oxidative or acidic conditions, which resulted in the formation of
2,3-O-p-methoxybenzylidene products
or degradation of the compound, respectively. We therefore decided
to postpone the removal of the PMB ethers to a later stage and first
removed the C-5-O-silyl group in 15 with
HF-pyridine as a fluorine source. Then, phosphitylation and subsequent
oxidation, as described above for β-ribosyl azide 9, provided α-azido-5-phosphorylribofuranoside 17.
Scheme 2
Synthesis of the α-Configured 1-Azido-5-phosphorylribofuranoside 17
The pyrophosphate linkage in
the target α- and β-azido
ADP-ribose building blocks was installed using our P(III)–P(V)
coupling method (Scheme ).[28] The required adenosine phosphoramidite 20 was synthesized from adenosine in 6 steps according to
a previously reported method (Scheme S3).[31] First the phosphates in 9 and 17 were liberated by removal of the Fm-groups with
triethylamine. Next, the phosphates 21 and 23 were coupled with adenosine amidite 20 upon activation
with dicyanoimidazole (DCI). Subsequent t-BuOOH mediated
oxidation of the P(III)–P(V) intermediate provided the partially
protected pyrophosphates. Deprotection of these building blocks started
with the removal of the cyanoethyl groups with DBU, after which treatment
with aqueous ammonia provided the fully deprotected β-azido-ADPr 22 and α-azido-ADPr 24, carrying the two
PMB ethers. β-Azido-ADPr 22 could be purified by
size exclusion chromatography (SEC) and was isolated as the ammonium
salt. On the contrary, due to hydrophobic interactions of the C-2-
and C-3-O-PMB groups of α-azido-ADPr 25, SEC was not efficient, and preparative reversed-phase
high-performance liquid chromatography (RP-HPLC) was required to obtain
the pure compound. Final removal of the PMB groups was executed using
a catalytic amount of HCl in hexafluoro-2-propanol[32] to yield 25 as triethylammonium salt after
workup and lyophilization.
Scheme 3
Synthesis of the 1′-Azide ADPr Analogues 22 and 25 Using Phosphoramidite Chemistry
The required peptides 26 and 27 were
synthesized using Fmoc-based solid phase peptide synthesis (SPPS),
incorporating propargyl glycine at the positions that are to carry
the His-type ADPr modification. Both peptides were obtained in good
yield and purity after RP-HPLC purification using an NH4OAC buffered eluent system.For the final Cu(I)-catalyzed conjugation,
a 1.5-fold molar excess
of the azido-ADPr analogue (22 or 25) was
added to an aqueous solution of the oligopeptide (26 or 27) after which the solution was degassed with argon (Scheme ). In parallel, a
fresh “click mixture” was prepared for every reaction
by adding an aqueous solution of sodium ascorbate to CuSO4 directly followed by tris(3-hydroxypropyltriazolylmethyl)amine (THPTA).
After addition of this mixture to the solution of the azide and the
alkyne, the conversion of the oligopeptide was monitored with liquid
chromatography–mass spectrometry (LC-MS). Upon complete conversion,
the crude products were desalted by SEC and subsequently purified
by preparative HPLC. Unfortunately, this tandem purification method
provided the desired products in moderate yields. Direct preparative
RP-HPLC proved to be more efficient and provided the desired products
in high purity.
Scheme 4
Synthesis of ADP-Ribosylated Histidine Mimetics via
Copper(I) Click
Chemistry
Two oligopeptides originating
from PARP1 (26) and HPF1 (27) have been
selected and synthesized with a propargylglycine incorporated at the
location of the histidine. Depending on the ADPr analogue used, an
α- or β-configured conjugate is formed. Hence, a total
of four ADPr conjugates 1–4 are obtained.
Synthesis of ADP-Ribosylated Histidine Mimetics via
Copper(I) Click
Chemistry
Two oligopeptides originating
from PARP1 (26) and HPF1 (27) have been
selected and synthesized with a propargylglycine incorporated at the
location of the histidine. Depending on the ADPr analogue used, an
α- or β-configured conjugate is formed. Hence, a total
of four ADPr conjugates 1–4 are obtained.Having obtained the triazole mimetics of ADP-ribosylated
histidine
peptides, we set out to investigate the enzymatic turnover of this
modification (Figure A). Peptides 1–4 were incubated in the presence
of different human (ADP-ribosyl)hydrolases and nudix hydrolase 5 (NudT5)
for 1 h at 30 °C. The former may catalyze the breakage of the N-glycosidic bond of the ribosyltriazole, while the latter
converts the released ADPr into adenosine monophosphate (AMP), which
was quantified using the AMP-Glo assay.[33] As a positive control, the samples were incubated in the presence
of NudT16, which in contrast to NudT5 can hydrolyze ADPr that is conjugated
to a peptide.[34] Although most human hydrolases
were unable to remove ADPr from the peptides, we observed a consistent
minor turnover (∼8.2%) for the HPF1-α peptide 4, indicating that our developed isostere is indeed a functional mimic
of ADP-ribosylated histidine. Interestingly, ARH3 appeared unable
to convert PARP1-α (2), which could suggest that
the removal of His-ADPr modifications is sequence-dependent.[35] These findings were substantiated in a time-course
experiment (Figure B), which showed the steady enzymatic conversion of 4 and the resistance of 2 toward enzymatic turnover.
Figure 2
Enzymatic
hydrolysis of interglycosidic linkages in ADP-ribosylated
histidine mimetic peptides 2(α), 1(β), 4(α), and 3(β). (A) Hydrolase
activity against the various peptides was assessed by monitoring AMP
release directly (NudT16) or converting released ADPr via NudT5 to
AMP. AMP was measured using the AMP-Glo assay (Promega). Samples are
background corrected and normalized to NudT16 activity. (B) Time-course
experiment of histidine isosteres 2(α) and 4(α) with ARH3. Time points taken up to 24 h. Data of
both experiments represent mean values ± SD measured in triplicates.
Enzymatic
hydrolysis of interglycosidic linkages in ADP-ribosylated
histidine mimetic peptides 2(α), 1(β), 4(α), and 3(β). (A) Hydrolase
activity against the various peptides was assessed by monitoring AMP
release directly (NudT16) or converting released ADPr via NudT5 to
AMP. AMP was measured using the AMP-Glo assay (Promega). Samples are
background corrected and normalized to NudT16 activity. (B) Time-course
experiment of histidine isosteres 2(α) and 4(α) with ARH3. Time points taken up to 24 h. Data of
both experiments represent mean values ± SD measured in triplicates.In conclusion, we have described the synthesis
of both α-
and β-configured ADPr-azide analogues that were successfully
used to prepare mimetics of ADP-ribosylated histidine using CuAAC.
Initial screening of the peptides against a collection of human ADPr
hydrolases revealed that ARH3 is able to hydrolyze the N-glycosidic
triazole-ribose linkage of HPF1-α 4, while PARP1-α 2 remained unscathed. Not only do these results suggest that
ARH3 is likely able to remove the ADPr modification from histidine
residues in the right sequential context,[35] but it also demonstrates that the peptides presented here provide
useful tools for the further study of the interactions of the His-ADPr
modification with either binders or hydrolases. Our current efforts
in the synthesis of peptides with native ADP-ribosylated histidine
will hopefully further elucidate the process of His-ADPr demodification
in the near future.
Authors: Qiang Liu; Hans A V Kistemaker; Sagar Bhogaraju; Ivan Dikic; Herman S Overkleeft; Gijsbert A van der Marel; Huib Ovaa; Gerbrand J van der Heden van Noort; Dmitri V Filippov Journal: Angew Chem Int Ed Engl Date: 2018-01-08 Impact factor: 15.336
Authors: Sejal Vyas; Ivan Matic; Lilen Uchima; Jenny Rood; Roko Zaja; Ronald T Hay; Ivan Ahel; Paul Chang Journal: Nat Commun Date: 2014-07-21 Impact factor: 14.919
Authors: Hans A V Kistemaker; Aurelio Pio Nardozza; Herman S Overkleeft; Gijs A van der Marel; Andreas G Ladurner; Dmitri V Filippov Journal: Angew Chem Int Ed Engl Date: 2016-07-28 Impact factor: 15.336
Authors: Orsolya Leidecker; Juan José Bonfiglio; Thomas Colby; Qi Zhang; Ilian Atanassov; Roko Zaja; Luca Palazzo; Anna Stockum; Ivan Ahel; Ivan Matic Journal: Nat Chem Biol Date: 2016-10-10 Impact factor: 15.040
Authors: Jim Voorneveld; Johannes G M Rack; Ivan Ahel; Herman S Overkleeft; Gijsbert A van der Marel; Dmitri V Filippov Journal: Org Lett Date: 2018-06-27 Impact factor: 6.005
Authors: Matthias Altmeyer; Simon Messner; Paul O Hassa; Monika Fey; Michael O Hottiger Journal: Nucleic Acids Res Date: 2009-04-16 Impact factor: 16.971
Authors: Sara C Buch-Larsen; Ivo A Hendriks; Jean M Lodge; Martin Rykær; Benjamin Furtwängler; Evgenia Shishkova; Michael S Westphall; Joshua J Coon; Michael L Nielsen Journal: Cell Rep Date: 2020-09-22 Impact factor: 9.423